ADZENYS XR-ODT in Children (4 to <6 Years) Diagnosed With Attention-deficit/Hyperactivity Disorder
Status:
WITHDRAWN
Trial end date:
2025-09-05
Target enrollment:
Participant gender:
Summary
This is a randomized, double-blind, flexible dose-titration, placebo-controlled, parallel-group study designed to evaluate the efficacy, safety, and tolerability of ADZENYS XR-ODT compared to placebo in children with ADHD.